124 related articles for article (PubMed ID: 9309153)
1. [Development of new antitumor reagents which block the cell cycle progression].
Osada H
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1541-6. PubMed ID: 9309153
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
4. Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53.
Park MJ; Kim EH; Park IC; Lee HC; Woo SH; Lee JY; Hong YJ; Rhee CH; Choi SH; Shim BS; Lee SH; Hong SI
Int J Oncol; 2002 Aug; 21(2):379-83. PubMed ID: 12118335
[TBL] [Abstract][Full Text] [Related]
5. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
McInnes C
Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
[TBL] [Abstract][Full Text] [Related]
6. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Patel V; Lahusen T; Sy T; Sausville EA; Gutkind JS; Senderowicz AM
Cancer Res; 2002 Mar; 62(5):1401-9. PubMed ID: 11888912
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
8. [G1 block of the cell cycle during differentiation of F9 cells correlates with accumulation of inhibitors of the activity of cyclin-kinase complexes of proteins p21/Waf1 and p27/Kip].
Malashicheva AB; Kisliakova TV; Pospelov VA
Tsitologiia; 2002; 44(7):649-55. PubMed ID: 12455373
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic.
Kakeya H; Onose R; Liu PC; Onozawa C; Matsumura F; Osada H
Cancer Res; 1998 Feb; 58(4):704-10. PubMed ID: 9485024
[TBL] [Abstract][Full Text] [Related]
10. Cyclins and related kinases in cancer cells.
Malumbres M
J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
[TBL] [Abstract][Full Text] [Related]
13. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
14. Bioprobes for investigating mammalian cell cycle control.
Osada H
J Antibiot (Tokyo); 1998 Nov; 51(11):973-82. PubMed ID: 9918389
[TBL] [Abstract][Full Text] [Related]
15. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
16. Early development of cyclin dependent kinase modulators.
Roy KK; Sausville EA
Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
[TBL] [Abstract][Full Text] [Related]
17. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
Vermeulen K; Van Bockstaele DR; Berneman ZN
Cell Prolif; 2003 Jun; 36(3):131-49. PubMed ID: 12814430
[TBL] [Abstract][Full Text] [Related]
18. Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.
Nugiel DA; Etzkorn AM; Vidwans A; Benfield PA; Boisclair M; Burton CR; Cox S; Czerniak PM; Doleniak D; Seitz SP
J Med Chem; 2001 Apr; 44(9):1334-6. PubMed ID: 11311054
[No Abstract] [Full Text] [Related]
19. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
Haesslein JL; Jullian N
Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
[TBL] [Abstract][Full Text] [Related]
20. Phosphatases as targets for cancer treatment.
Lazo JS; Wipf P
Curr Opin Investig Drugs; 2009 Dec; 10(12):1297-304. PubMed ID: 19943201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
